Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma

Background: Vorolanib (X-82, CM082) is a multi-target tyrosine kinase inhibitor. This study aimed to evaluate the tolerability, safety, pharmacokinetics and antitumor activities of vorolanib plus everolimus (an inhibitor of mammalian target of rapamycin). Methods: Patients had histologically or cyto...

Full description

Bibliographic Details
Main Authors: Xinan Sheng, Xieqiao Yan, Zhihong Chi, Chuanliang Cui, Lu Si, Bixia Tang, Siming Li, Lili Mao, Bin Lian, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Lieming Ding, Li Mao, Jun Guo
Format: Article
Language:English
Published: Elsevier 2020-05-01
Series:EBioMedicine
Subjects:
Renal cell carcinoma
Vorolanib
CM082
Everolimus
Combination therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396420301304

Internet

http://www.sciencedirect.com/science/article/pii/S2352396420301304

Similar Items